Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. Dexfenfluramine, the dextrorotatory isomer of fenfluramine, is indicated for use in the management of obesity in patients with a body mass index of > or = 30 kg/m2, or > or = 27 kg/m2 in the presence of other risk factors. Unlike fenfluramine, dexfenfluramine is a pure serotonin agonist. Dexfenfluramine increases serotonergic activity by stimulating serotonin (5-hydroxytryptamine; 5-HT) release into brain synapses, inhibiting its reuptake into presynaptic neurons and by directly stimulating postsynaptic serotonin receptors. Dexfenfluramine reduces blood pressure, percent glycosylated hemoglobin, and concentrations of blood glucose and blood lipids, but these benefits may be indirect. Dexfenfluramine may also be of some value in controlling eating habits in diabetic patients, preventing weight gain after smoking cessation, and treating bulimia, seasonal affective disorder, neuroleptic-induced obesity, and premenstrual syndrome. Dexfenfluramine's most frequent adverse effects are insomnia, diarrhea, and headache; it has also been associated with primary pulmonary hypertension. The drug should not be combined with other serotonergic agonists because of the risk of serotonin syndrome. The recommended dosage is 15 mg twice daily. Dexfenfluramine is effective in the treatment of obesity in selected patients. Because its efficacy is lost after six months of continuous treatment, it should be viewed primarily as an adjunct to diet and exercise. Dexfenfluramine was approved by the FDA in 1996 and has been widely used for the treatment of obesity. However, Dexfenfluramine was removed from the U.S. market in 1997 following reports of valvular heart disease and pulmonary hypertension.

Oxaflumazine acid disuccinate, a neuroleptic drug, was studied in the treatment of psychotic children in a pedopsychiatric environment.

Ufenamate is a topical analgesic. It is indicated for pain and inflammation associated with musculoskeletal and joint disorders. It is a COX inhibitor. Ufenamate is freely soluble in oil and is poorly soluble in water. It is used in the form of ointments or creams. It is manufactured under the brand name Combec in Japan. It is also an ingredient of Fenazol Ointment 5%, used in Japan for the treatment of eczema, dermatitis and herpes zoster.

Calmatel contains piketoprofen and belongs to the group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). This medicine is indicated in adolescents over 12 years and adults for local pain relief and mild and occasional inflammation caused by: small contusions, bruises, strains; torticollis or other contractures; lumbago; minor sprains caused because of a twist.

Morniflumate is a non-steroidal anti-inflammatory drug and represent as a beta-morpholinoethyl ester of niflumic acid, which is rapidly hydrolyzed in the plasma, releasing the free acidic form, the molecule responsible for the pharmacological effects. It was shown, that morniflumate was effective in the treatment of chronic recurring bronchitis and inhibited cyclooxygenase-1, 2 (COX-1, 2). Morniflumate has a 30-year history of clinical use, particularly for the treatment of pain associated with pediatric ear-nose-throat (ENT) infection. In addition, it appears to be a valid and well-tolerated alternative to other NSAIDs, or to antibiotics, for the treatment of pain and other symptoms of soft tissue inflammation.

Acreozast is an orally active antiallergic agent, which has anti-inflammatory activity. It was undergoing phase II clinical trials in Japan for the following condition: Asthma and Atopic dermatitis. Toyobo discontinued the development of acreozast in 1996.

Balazipone (OR 1364), an anti-inflammatory drug that was participated in clinical trials Phase-I for Crohn's disease in Finland.

Dimethyl phthalate, an organic compound, is used as repellents. This compound is a pollutant that is very harmful to organisms due to its mutagenicity, teratogenicity and carcinogenicity. It was discovered, that dimethyl phthalate could alter the biological function of the one of the most important bacteria in the environment, P. fluorescens.

Antrafenine (SL 73033 or 2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl 2-[[7-(trifluoromethyl)-4-quinolinyl]amino]benzoate) showed marked analgesic activity, long duration of action, and excellent tolerance in pharmacological and toxicological studies. Antrafenine exerts anti-inflammatory effects. It has been studied in the treatment of osteoarthritis.

Broperamole has been studied as an anti-inflammatory agent.